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Abstract
Background: The human papillomavirus (HPV) vaccine is an underutilized cancer control practice in the United
States. Although individual contextual factors are known to impact HPV vaccine coverage rates, the impact of
macro-level elements are still unclear. The aim of this analysis was to use HPV vaccination rates to explore the
underuse of an evidence-based cancer control intervention and explore broader-level correlates influencing
completion rates.
Methods: A comprehensive database was developed using individual-level date from the National Immunization
Survey (NIS)-Teen (2016) and state-level data collected from publically available sources to analyze HPV vaccine
completion. Multi-level logistic models were fit to identify significant correlates. Level-1 (individual) and level-2
(state) correlates were fitted to a random intercept model. Deviance and AIC assessed model fit and sampling
weights were applied.
Results: The analysis included 20,495 adolescents from 50 U.S. states and the District of Columbia. Teen age,
gender, race/ethnicity, and maternal education were significant individual predictors of HPV completion rates.
Significant state-level predictors included sex education policy, religiosity, and HPV vaccine mandate. States with the
lowest HPV coverage rates were found to be conservative and highly religious. Little variation in vaccine
exemptions and enacted sex and abstinence education polices were observed between states with high and low
HPV vaccine coverage suggesting various contextual and situational factors impact HPV vaccine completion rates.
Conclusions: Given that gender, religiosity, political ideology, and education policies are predictors of HPV vaccine
completion, the interaction and underlying mechanism of these factors can be used to address the underutilization
of the HPV vaccine.
Keywords: Human papillomavirus (HPV), National Immunization Survey-Teen, Cancer prevention, Mis-implementation
Background
In the United States, human papillomavirus (HPV) is the
most common sexually transmitted infection causing
genital warts and HPV-related cancers [1]. HPV trans-
mission can occur through vaginal, anal, or oral sex with
an HPV-infected individual [1]. As symptoms can de-
velop years after infected with HPV, onset of the virus
can be difficult to diagnosis [1]. Currently, about 79 mil-
lion people are infected with HPV and an additional 14
million cases are projected annually in the United States
[1]. Each year, about 30,000 Americans develop cancer
as a result of an HPV infection with incidence and
prevalence of HPV-related cancers disproportionately
higher in Hispanic and African American woman com-
pared to their counterparts [2–4].
Efficacy studies have indicated HPV vaccines are a highly
effective prevention tool prior to HPV exposure [5, 6]. As
a result, the Advisory Committee on Immunization Prac-
tices (ACIP) recommends routine vaccinations for all chil-
dren and adolescents beginning as early as age nine [7].
Vaccines are known to be one of the few highly effective
public health strategies that address many preventable
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diseases, such as HPV-related cancers and infections [8].
Gradual progress to improve access to HPV vaccines and
initiatives to increase vaccine uptake have been seen in re-
cent years. Efforts include: 1) communication campaigns
and strategies, 2) mandating private and public insurance
plans to provide coverage for preventative services, includ-
ing the HPV vaccine and testing, under the Affordable
Care Act and Medicaid Expansion, 3) distribution of HPV
vaccines to uninsured and low-income individuals by the
Vaccine for Children program, and 4) improving health
through benchmarks such as Healthy People 2020, which
sets to achieve an 80% HPV vaccine coverage rate among
U.S. adolescents [9–11]. Yet, HPV vaccination coverage is
drastically lower than other childhood vaccines with a
2017 national average of 43%, including males and fe-
males, compared to a coverage of 91.1% for measles,
mumps, and rubella (MMR) vaccine [12, 13].
Attitudes and beliefs that HPV is a low health priority
and vaccination is an elective health measure have re-
sulted in low adherence to HPV vaccine guidelines [14].
Considerable attention on individual, provider, and fam-
ily contextual factors explaining low HPV adherence
(e.g., vaccine safety and efficacy knowledge), acceptability
(e.g., parental intent to vaccinate), and barriers (e.g., pro-
viders informed of HPV vaccine schedule/updates) has
been observed in the literature [14–18]. Reliance on
high-risk strategies for the HPV vaccine (e.g., identify gen-
etic dispositions and disease risk/development) to
emphasize prevention and screening, specifically among
those at high-risk of an HPV infection, has been aban-
doned as these efforts are unsuccessful and high cost with
limited potential [19, 20]. A shift to a population-based
strategy (e.g., adopted normality of seat belt usage) will
focus HPV vaccine coverage efforts on broader-level fac-
tors to reduce the risk of HPV infections by altering be-
havior norms and have a wider reach [19].
In order to explore opportunities to enhance HPV vac-
cine uptake, the aim of this paper is to study the com-
bination of individual (e.g., gender, race) and macro-level
factors (e.g., political environment, state religiously, sex/
abstinence education polices) potential influences on
HPV vaccine completion rates as limited evidence is
available. Further understanding these relationships, will
not only broaden the evidence in the literature to con-
sider influences beyond the individual, but provide guid-
ance and support to leaderships and facilitators whom
have decision-making power in HPV vaccine-related ac-
tivities. These findings can potentially translate into suc-
cessful implementation of HPV vaccine interventions
and identify potential influences hindering their
utilization. We hypothesize that broader-level factors, in
addition to individual-level influences, highlights poten-
tial modifiable and non-modifiable HPV vaccine barriers
influencing suboptimal HPV vaccine adherence
nationally. More specifically, we seek to (1) explore pos-
sible factors of high and low HPV vaccine coverage
rates, and (2) illustrate the current HPV vaccine cover-
age rates across the United States.
Methods
For our analyses, a comprehensive database was created




The National Immunization Survey (NIS)-Teen (2016) is
a cross-sectional survey which estimates vaccine cover-
age rates among 13–17 year old teens in the United
States using random digit dialing conducted by the
National Center for Immunization and Respiratory
Diseases and the National Center for Health Statistics
within the Centers for Disease Control and Prevention
(CDC) [21, 22]. Telephone interviews were conducted
with parents regarding their teen’s vaccination history
and teen and family sociodemographic factors (e.g., teen
age and maternal education). With parental consent, the
teen’s medical provider(s) were contacted to request
medical records to verify vaccine history [21, 22]. We ex-
cluded teens without medical provider-confirmed vaccin-
ation history [22]. The NIS-Teen was approved by the
Ethics Review Board of the National Center for Health
Statistics, Centers for Disease Control and Prevention.
State-level data
Funding appropriated for HPV vaccination promotion ef-
forts in 2017 and state and local public health governance
(2015) was taken from the Centers for Disease Control
and Prevention (CDC) websites [23, 24]. The 2010 state
population was obtained from the United States Census
Bureau webpage [25]. State-wide policies related to sexual
education and vaccination requirements were taken from
the Guttmacher Institute (2017) and the Immunization
Action Coalition (2017), respectively [26, 27]. Religious
and political opinions by state were available from the
Pew Research Center (2014) [28, 29]. Individual and
state-level data were obtained at the most recent report
for each source at the time of analysis.
Outcome specification
Vaccine coverage, or completion data, was based on
medical records from providers and vaccines adminis-
tered after the NIS-Teen interview were excluded [22].
HPV vaccine completion was defined as having ≥3 HPV
shots or ≥ 2 HPV shots with the first shot received be-
fore age 15 and the interval between the 1st and 2nd
shots at least 5 months and 4 days apart. Teens were
considered up to date on their Tdap (Tetanus,
Franco et al. BMC Public Health          (2019) 19:246 Page 2 of 9
Diphtheria, and Pertussis) vaccination completion if they
had received ≥1 shot since age 10 and for MMR vaccine
if they had received ≥2 shots at the time of the survey.
Exposure specification
Teen and family correlates
Covariates at the teen and family-level were chosen from
the NIS-Teen dataset based on previous literature and
included teen age, gender, race/ethnicity; maternal edu-
cation; family poverty status; and whether a provider had
recommended an HPV vaccine series for the child. Indi-
cator variables were used to examine race and ethnicity
of the teen as Non-Hispanic White, Non-Hispanic Black,
Hispanic, and Non-Hispanic other or mixed race. Pov-
erty status of the family was categorized as above or
below the federal poverty line, and maternal education
was dichotomized as up to a college graduate and col-
lege graduate or higher.
State correlates
State public health departments were categorized ac-
cording to their jurisdiction type as decentral, central,
mixed, or shared [24]. Funding was determined in mil-
lions of U.S. dollars from several CDC funding lines that
could be used towards HPV vaccine promotion efforts:
immunization & respiratory disease; vaccines for chil-
dren; HIV/AIDS and viral hepatitis; sexually transmitted
infection and tuberculosis prevention; chronic disease
prevention and health promotion, and cancer prevention
control. CDC funding per capita was calculated as the
total amount of CDC funding in the previously identified
categories divided by the 2010 population.
The presence of an HPV vaccine and sex education
mandate in state legislation, along with the type of
abstinence-only policy (e.g., whether abstinence was cov-
ered or stressed) were also examined as potential state
correlates. States that have “stressed abstinence” policies
strongly emphasizes abstinence as a standard teaching
[30]. Alternatively, “covered abstinence” education ad-
dresses abstinence and also includes information about
contraception [30]. Political ideology was categorized as
percent of the state identifying as conservative, moder-
ate, liberal, or those who did not know their political
ideology. Additionally, the religious tendency of a state
was expressed as the percent of the state identifying as
highly religious [29].
Statistical analysis
Multi-level models were fit to identify important corre-
lates of HPV vaccine completion and quantify relation-
ships with odds ratios and 95% confidence intervals (CI).
First an unconditional logistic model was fit without any
independent variables to calculate the intra-class correl-
ation for states. Random intercept models were then fit
with individual (level-1) and subsequently state (level-2)
correlates. Model fit was assessed using deviance and
Akaike information criterion (AIC). Sampling weights
calculated for the provider-confirmed data were taken
from the NIS-Teen data, which account for selection
and non-response probability and were rescaled to ac-
count for the multi-level nature of the data according to
best practice recommendations [31]. Models were fit
with and without rescaled sampling weights, and models
presented are those fit with sampling weights that were
rescaled to add up to the cluster size. There were no
missing data once the outcome variable, provider con-
firmed receipt of HPV vaccine, was selected.
Additionally, an analysis of education policy and
broader-level factors on HPV vaccine completion rates
was done. Sex and abstinence education policies were
coded into four groups based on comprehensiveness of
policy: (1) having both a sex and abstinence education
policy (SA-YY), (2) having a sex education only policy
and not an abstinence education policy (SA-YN), (3) not
having a sex education policy and having an abstinence
only education (SA-NY), and (4) not having either a sex
and abstinence education policy (SS-NN) (Table 3). Vac-
cine exemptions were also coded into three subgroups:
(1) medical vaccine exemption (M), (2) medical and reli-
gious vaccine exemption (MR), and (3) medical, reli-
gious, and personal vaccine exemption (MRP). HPV
vaccine completion rates, religiosity, political ideology,
and vaccine exceptions by high and low state vaccine
implementers were also analyzed. A national map to
visualize state-specific HPV vaccine completion was also
done. All statistical analyses were performed in SAS 9.4
(Cary, NC), MPlus Version 8, and ArcMap 10.5.1 [32].
Results
The 2016 NIS-Teen survey included 20,495 teens with
provider-confirmed vaccination history and were in-
cluded in our analyses, which was 49% of the inter-
viewed sample. The average adolescent age was 15 years
old with the majority of teens being Non-Hispanic
White and female (Table 1). State-level data included the
50 U.S. states and the District of Columbia. Table 2 illus-
trates that currently only the District of Columbia and
two states had enacted an HPV vaccine mandate (Rhode
Island and Virginia) with the majority in support of ab-
stinence education (Table 3). Most states identified as
highly religious and had a conservative political ideology.
Few had a centralized public health governance with the
majority of public health departments being decentra-
lized in the United States. Further, about $43 million
was potentially available for HPV vaccine promotion ef-
forts with a CDC funding per capita of approximately
$17 in 2016.
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Rhode Island (70.8%) and the District of Columbia
(62.0%) had the highest HPV vaccine coverage rates in
the United States. Those with the lowest HPV vaccine
coverage rates in 2016 were Wyoming, Mississippi,
South Carolina, Utah, and Texas. These states were
found to be more conservative and highly religious than
states with the highest coverage rates. Little variation
among these states regarding education polices and vac-
cine exemptions was observed. (Table 4 and Fig. 1).
As shown in Table 5, individual and state effects of
HPV vaccine completion were teen gender-female (OR,
1.65; 95% Cl,1.56–1.75), Hispanic teen race/ethnicity
(OR, 1.52; 95% Cl,1.36–1.69), Non-Hispanic Black teen
race/ethnicity (OR, 1.34; 95% Cl, 1.18–1.51), HPV vac-
cination recommended by healthcare provide (OR, 3.57;
95% 3.24–3.92), and HPV vaccine mandate (OR, 1.65;
95% Cl 1.16–2.35). Abstinence education, CDC funding
(per capita), and public health governance were found to
be non-significant model factors. Among teens,
Hispanics/Blacks, females, and those living below the
poverty line were more likely to complete the HPV vac-
cine series compared to their counterparts.
Additionally, states with sex education polices and an
HPV vaccine mandate were found to have higher com-
pletion rates. A larger percentage of highly religious
adults within a state had significantly lower rates of
HPV vaccine completion (with by far, the largest effect
estimate). Gender, political ideology, religiosity, and sex
education policy were not found to have similar impacts
on Tdap and MMR vaccination rates as the HPV vac-
cine. See Table 5 for other significant predictors of HPV
vaccine completion.
Discussion
This multi-level analysis using state and national data
found the significant predictors of HPV vaccine comple-
tion were the presence of an HPV vaccine mandate, re-
ligiosity, being female, and Hispanic or Black race/
ethnicity. Although we expect race, gender, living below
the poverty line, and maternal college education to be
indicative of higher HPV vaccine completion rates, the
effects of additional macro-level factors are important to
consider in improving suboptimal HPV vaccine adher-
ence. This suggests that a state’s sex and abstinence edu-
cation policy, religiosity, and political ideology may be
important correlates of HPV vaccine completion.
Our analysis suggests an 11-fold decrease in HPV vac-
cine completion rates among states with a higher per-
centage of religious adults. Religion has been found to
Table 1 Teen- and Family-level Characteristics
Mean SD
Teen age (years) 15.0 1.4
N %
HPV vaccine completion 9204 43.4
Teen race/ethnicity
Non-Hispanic White 12,883 63%
Non-Hispanic Black 1990 10%
Hispanic 3223 16%
Non-Hispanic other or mixed race 2379 12%
Teen gender – Female 9661 47%
Family below poverty line 3461 17%
Mother is a college graduate 9654 47%
Table 2 State-level Characteristics
N %
HPV mandate present 3 6%
Sex education policy present 25 56%
Abstinence only education policy present 37 88%
Stressed 26 70%
Covered 11 30%











Don’t Know 6.27 0.02
Center for Disease Control and Prevention Funding
Funding per capita (USD) $17.34 $21.72
Total CDC Funding (millions USD) 67.56 60.61
Immunization & Respiratory Disease 7.02 6.89
Vaccine for Children 1.87 1.78
HIV/AIDS, Viral Hepatitis, STI and TB Prevention 14.01 20.97
Chronic Disease Prevention and Health Promotion 14.71 10.27
Cancer Prevention Control 5.40 3.21
Table 3 State HPV Coverage Rates and Sex and Abstinence
Education Polices
Education Policy Setsa N (%) % HPV Vaccine Completion (SD)
Y-Sex, Y-Abstinence 22 (43) 45.0 (10.26)
Y-Sex, N-Abstinence 3 (6) 49.1 (11.49)
N-Sex, Y- Abstinence 15 (29) 40.9 (5.58)
N-Sex, N-Abstinence 11 (22) 44.6 (9.37)
aY Yes Policy Present, N No Policy Present
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influence immunization decisions as several states have
religious exemptions for school mandated vaccines. If
parents are religiously opposed to immunizing their chil-
dren against infectious disease such as tetanus or mea-
sles, the likelihood of vaccinating these teens for a
sexually transmitted disease like HPV poses a challenge
to vaccine completion rates. Although there is limited
evidence, the role of religion has been found to guide
decisions around certain health behaviors therefore in-
fluencing HPV vaccine acceptance and uptake [33, 34].
As most literature focuses on the intent to vaccinate
teens against HPV based on religious beliefs, few give in-
sights on religious impact on HPV vaccine completion.
A study in Utah found that non-religious females were
more likely to complete the HPV vaccine series (received
3 doses) than religious females [34]. A similar trend is
found in our study sample as states that had a higher
percentage of religious adults showed lower HPV vac-
cine completion rates. By considering the religious cli-
mate, states with a denser religious population (e.g.,
Utah) can benefit from faith-based HPV vaccine inter-
ventions delivered by religious leaders to increase cover-
age rates. For example, Body & Soul, a faith-based
intervention, sought to increase vegetable and fruit con-
sumptions among African Americans by partnering with
churches to encourage diet change [35]. By taking this
Table 4 Top 5 High and Low HPV Coverage Statesa





completion (%)Conservative (%) Moderate (%) Liberal (%)
High State HPV Coverage Rates
RI 49 26 35 30 SA-YY MR 70.8
DC 53 15 39 36 SA-YN MR 62.0
DE 52 26 40 25 SA-YY MR 56.9
MA 33 23 35 36 SA-NN MR 56.6
ME 34 34 33 30 SA-YY MRP 56.0
Low State HPV Coverage Rates
TX 64 39 32 21 SA-NY MRP 32.9
UT 64 45 31 20 SA-YY MRP 30.5
MS 77 45 30 19 SA-YY M 29.1
SC 70 43 35 15 SA-YY MR 29.1
WY 54 41 33 17 SA-NN MR 26.7
aOverview of the states with the highest and lowest HPV completion rates in the United States and current comparison of political ideology, religiosity, education
policy, and vaccine exemptions per state
bSA-YY sex-YES & abstinence-YES, SA-YN Sex-YES & abstinence-NO, SA-NY Sex-NO & abstinence-YES, SA-NN Sex-NO & abstinence-NO
cM Medical vaccine exemption, MR Medical and religious vaccine exemption, MRP Medical, religious, and personal vaccine exemptio
Fig. 1 HPV vaccine completion by state, 2016
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approach, challenges faced by current traditional inter-
ventions targeted towards the general public can be
overcome to improve HPV knowledge, awareness, and
acceptance as well as HPV vaccine coverage among reli-
gious communities.
Little is known about how strongly and consistently
state-level polices impact HPV health outcomes, but these
results indicate certain policies may impact HPV vaccine
coverage rates. There is significant political opposition
and criticism to enact legislation mandating HPV vaccin-
ation for adolescents [36, 37]. As a result, only two states
and the District of Columbia have successfully passed le-
gislation requiring teens to be vaccinated [37]. Dempsey et
al. suggests the use of stringent school mandates can im-
prove HPV vaccine completion [38]. They predict a 90%
completion with the presence of a school mandate can be
achieved in 50 years opposed to a 79% completion in 43
years without a school mandate in place [38]. In the
United States, requiring other childhood vaccines (MMR,
Tdap) for school enrollment has been successful in
maintaining coverage rates, but we are missing the oppor-
tunity to widely accept and use school-mandates for the
HPV vaccine. Ineffective policy implementation is limiting
the potential of a known evidence-based intervention to
prevent HPV-related infections and cancers. Our results
suggest that suboptimal utilization of the HPV vaccine
may be increased through HPV school-mandates by re-
quiring teens to be vaccinated for school enrollment.
Despite strong support for abstinence-only education
policies among some stakeholders, [39] it has been found
that they do not delay sexual initiation, prevent teen preg-
nancies, number of sexual encounters, or reduce STI rates
[40, 41]. Although enactment of sex education-only pol-
icies showed significance on HPV vaccine completion
rates in our analyses, on average, states with both sex and
abstinence education policies had a slightly higher HPV
coverage rate compared to states that had not enacted any
education policies. This finding suggests that other con-
textual factors are driving HPV vaccine completion in
states that do not have either policy in place.
Table 5 Associations between individual and state-level factors and vaccine completion
Full model Reduced modela
OR 95% CI p-value OR 95% CI p-value
Teen age 1.17 1.13 1.21 < 0.0001 1.17 1.13 1.21 < 0.0001
Teen race/ethnicity
Non-Hispanic White (ref) 1 1
Non-Hispanic Black 1.41 1.24 1.62 < 0.0001 1.42 1.24 1.62 < 0.0001
Hispanic 1.61 1.45 1.79 < 0.0001 1.61 1.45 1.79 < 0.0001
Non-Hispanic other or mixed race 1.27 1.15 1.40 < 0.0001 1.27 1.15 1.40 < 0.0001
Teen gender – Female 1.50 1.41 1.60 < 0.0001 1.50 1.41 1.60 < 0.0001
Family below poverty line 1.61 1.47 1.77 < 0.0001 1.61 1.47 1.77 < 0.0001
Mother is a college graduate 1.13 1.04 1.23 0.018 1.13 1.04 1.23 0.017
Provider recommended HPV vaccine 3.56 3.24 3.92 < 0.0001 3.57 3.24 3.92 < 0.0001
HPV mandate present 1.55 1.02 2.36 0.082 1.71 1.19 2.45 0.015
Percent of state identifying as highly religious 0.13 0.06 0.26 < 0.0001 0.13 0.08 0.20 < 0.0001
Sex education policy present 1.09 0.96 1.23 0.269
Percent of state identifying as conservative 0.67 0.23 1.99 0.545
Abstinence only education policy absent (ref) 1
Abstinence stressed 1.05 0.91 1.21 0.576
Abstinence covered 1.09 0.91 1.23 0.437
CDC funding per capita (USD) 1.00 0.99 1.02 0.726
Public Health Department Type
Decentral (ref) 1
Central 1.06 0.91 1.23 0.509
Mixed 1.07 0.82 1.39 0.693
Shared 1.01 0.84 1.21 0.939
aLogistic regression models were fit to quantify the relationships between individual- and state-level factors and HPV vaccine completion. The full model
represents all correlates that were examined, and the reduced model includes only those correlates that were statistically significantly associated (p < 0.05) with
HPV vaccine completion
OR Odds ratio, CI Confidence interval
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Furthermore, as shown in other studies, [42–45] our
results indicate females are more likely than males to
complete the HPV vaccine series. There are several fac-
tors to consider that are resulting in higher HPV vaccine
completion rates among females. Initially, the identifica-
tion of HPV as a gender-specific disease has led to a
feminization of the HPV vaccine, contributing parental
opposition to vaccinate their male children [42, 46]. Al-
though both genders are at risk for HPV, it is estimated
that males are more likely than females to contract an
HPV infection in their lifetime [4, 42]. Despite this, the
burden of HPV screening, vaccination, and treatment falls
heavily on woman [42, 46]. Several efforts are shifting the
mentality of HPV as a female-specific disease, including
media campaigns that incorporate messages around male
vaccination, the addition of males to the ACIP HPV vac-
cine recommendations in 2010, and a growing body of
evidence of the burden of disease in both males and fe-
males [37]. Further, our results strongly indicate that
healthcare providers play a major role in HPV vaccine
completion rates. Gender bias among healthcare pro-
viders’ recommendations could also be influencing HPV
vaccination rates among males [42, 45]. As HPV vaccine
recommendations by providers has been shown to influ-
ence parental acceptance to vaccinate their teen, there is a
discrepancy in receiving HPV vaccine recommendations
by gender [45, 47]. Parents report healthcare providers are
less likely to recommend the HPV vaccine if their child is
male compared to a female child indicating providers need
to be aware of the potential effects of these biases [45, 48].
This further stress the importance of provider recommen-
dation for HPV vaccine completion, regardless of gender,
to achieve desired coverage rates. Altogether, these factors
may explain situational factors influencing parental deci-
sions to vaccinate male teens.
There are many factors that affect HPV vaccine comple-
tion rates as is not reliant on a single policy or
individual-level characteristics. Gender, religiosity, political
ideology, and education polices are independent predic-
tors of HPV vaccine completion rates as they were not
found to be present in Tdap and MMR vaccine comple-
tion models. Thus, further research should consider the
complexity of the political and religious environment as
well as other state-level policies must be considered when
trying to the address the underutilization of this cancer
prevention vaccine. Roberts et al. identified a combination
of state-level policies associated with higher vaccine up-
take, including Medicaid expansion, HPV vaccine school
mandates, HPV vaccination through pharmacies, and sex
education policies [36]. This suggests that specific policies
have significant influences on HPV vaccine adherence and
their interactions within states is needed to understand
the contextual and situational factors that contribute or
prevent a teen from completing the HPV vaccine series.
This analysis can also serve as an example showing
how mis-implementation of an evidence-based cancer
intervention is occurring. According to Padek et al.,
mis-implementation is the continuation of ineffective
programs and policies or the discontinuation of effective
ones [49]. The implementation of evidence-based inter-
ventions such as the HPV vaccine has the potential to
prevent HPV-related cancers and infections. However,
the underuse of this population-based intervention has
not achieved their potential effect on HPV-related can-
cer outcomes. This could perhaps be explained by the
discontinuation of this evidence-based intervention at
the individual and state-level. There could be a variety of
factors at play on why these programs or policies are
discontinued or not implemented at all and a better un-
derstanding of the demographics which underutilize this
vaccine could help facilitate more successful implemen-
tation of programs or policies.
Next steps should explore current HPV vaccine-related
policies and initiatives in states not having neither educa-
tion policy to gain insight into other activities contributing
to HPV vaccine completion rates. As states that enacted
sex education policies were found to have the highest
coverage rates among any policy combination, more study
of the effects of comprehensive sex education to increase
HPV vaccine coverage rates is supported.
Although the governance of state health departments
were not significant predictors of HPV vaccine comple-
tion rates, research to understand the role of state health
departments on current efforts, barriers, and allocation
of resources regarding cancer control programs is essen-
tial to identify the mis-implementation at a state-level.
Considering and understanding the role of factors lead-
ing to mis-implementation of cancer control programs
and policies regarding HPV vaccine can prevent missed
opportunities to appropriately implement these efforts.
Lastly, learning and further exploring elements that
contribute to low and high vaccine coverage rates among
states can inform the development of comprehensive
HPV vaccine interventions and policies to increase the
utilization of the HPV vaccine in the United States.
Limitations
We acknowledge that there are several limitations to this
analysis. The cross-sectional nature of our study limits
our ability to draw any firm conclusions on the
macro-level contributing factors to low-HPV vaccine up-
take. Evidence shows that provider-level recommenda-
tions has a significant influence on patient uptake of the
vaccine [50–52].However, given other macro-level fac-
tors, provider recommendations may vary greatly by
geographic region. This would be pertinent to explore
further in future analyses. Further, while the use of a na-
tionally representative sample is a major strength of this
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analysis, the pooling of various sources limits the
generalizability of results and cannot be used to predict
future HPV vaccine completion rates.
Conclusion
Despite the study’s limitations, this analysis highlights the
potential impacts of broader contextual factors effects on
HPV vaccine coverage rates in the United States. found
that in addition to individual-level correlates (e.g., teen
age, race, socioeconomic status), policy, political ideology,
and religiosity state-level factors are significant correlates
of HPV vaccine completion rates. However, there is lim-
ited evidence on how these factors interact with each
other within a state to promote HPV vaccine efforts. Fur-
ther studies need to continue to identify state and
local-level factors that contribute to HPV vaccine uptake
and adherence as well as understand the underlying
mechanisms of these factors within states of high and low
HPV vaccine coverage rates. An in-depth case analysis of
these states may provide insight on effective strategies, ini-
tiatives, and policies along with overcome challenges and
barriers to serve as a guidance for other states and better
inform HPV vaccine interventions.
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